A Pre-Approval Information Exchange (PIE) Webinar, presented by Rhythm Pharmaceuticals, Inc.

Acquired HO is a devastating disease that occurs most frequently after hypothalamic injury resulting from surgical resection or radiation of brain tumors, TBI, or stroke. It is characterized by accelerated weight gain, reduced energy expenditure, and hyperphagia, and it carries significant long-term burdens for patients and their caregivers. This presentation will review efficacy and safety results from a clinical trial evaluating an investigational treatment for acquired HO.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

Rare diseases pose significant challenges for managed care, requiring innovative solutions and a deep understanding of patient needs. Join this virtual event spotlighting four rare diseases. Through discussion of emerging therapies, patient journeys, and managed care strategies, attendees will gain practical insights for improving access, supporting adherence, and advancing equitable care for those affected by rare diseases.

11am-12:15 pm
Rare Disease Spotlight: Disease Burden, Unmet Needs, and Amplifying the Patient Voice - Managed Care Insights into Hereditary Angioedema and Beta Thalassemia

2-3:15pm ET
Rare Disease Spotlight: Disease Burden, Unmet Needs, and Amplifying the Patient Voice - Managed Care Insights into Myasthenia Gravis and Phenylketonuria

A Pre-Approval Information Exchange (PIE) Webinar, presented by Novo Nordisk Inc.

Denecimig is a novel FVIIIa mimetic agent currently under investigation for the treatment of hemophilia A (congenital FVIII deficiency) with or without FVIII inhibitors. Denecimig has not been approved for any indication by any regulatory authority. This webinar will offer healthcare decision-makers an overview of the burden of disease in patients with hemophilia A, a detailed introduction to denecimig, its delivery (dosing and administration), and a summary of its clinical trial program.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA.

An AMCP LINK Webinar.

As 2026 begins, prior authorization and utilization management remain at the center of payer strategy and regulatory scrutiny. This Prior Authorization and Utilization Management LINKs kickoff webinar will explore the current policy landscape - what's changing, what's proposed, and what it means for your daily work. This will be a discussion-forward session focused on:

• The State of Play
• Disconnects and Realities
• Operational Impacts

Join us to share insights, surface pain points, and help shape AMCP's advocacy and practice agenda for 2026. Your voice will guide where policy meets practice.

Join AMCP Government Affairs staff for a look at anticipated legislation and regulation in 2026 that will impact the practice of managed care pharmacy. Important issues being debated by lawmakers this year include pharmacy benefit manager reform, most-favored-nation drug pricing, direct-to-consumer drug sales, 340B reform, and more. The Government Affairs team will also discuss the government funding package to be passed by January 31 and health care implications of the Congressional midterm elections.

Hello Precision Medicine Enthusiasts!

Join us for our upcoming LINK call, where we’ll explore the real-world impact of clinical utility in precision medicine. We’ll kick things off with a quick, lively overview— to get us thinking about “how does this help patients and providers?”

After the intro, we’ll break out into working groups to tackle some of the most important questions in clinical utility. We can't wait to hear your ideas!

Breakout 1: Defining and Measuring Clinical Utility

Breakout 2: Payer and Policy Considerations

Breakout 3: Operationalizing Clinical Utility in Practice